Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Inmed Pharmaceuticals Inc (IMLFF)

Inmed Pharmaceuticals Inc (IMLFF)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]

Fundamentals

See More
  • Market Capitalization, $K N/A
  • Shares Outstanding, K N/A
  • Annual Sales, $ 0 K
  • Annual Income, $ 0 K
  • 60-Month Beta N/A
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 3.30
  • Price/Earnings ttm N/A
  • Earnings Per Share ttm N/A
  • Most Recent Earnings N/A on N/A
  • Next Earnings Date N/A
  • Annual Dividend & Yield N/A (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Price Performance

See More
Period Period Low Period High Performance
1-Month
4.3148 +17.04%
on 07/07/20
8.2170 -38.54%
on 06/11/20
-2.6885 (-34.74%)
since 06/10/20
3-Month
4.0590 +24.41%
on 04/27/20
10.4280 -51.57%
on 06/04/20
+0.2518 (+5.25%)
since 04/09/20
52-Week
3.5772 +41.17%
on 03/16/20
11.0880 -54.46%
on 09/10/19
-3.9491 (-43.88%)
since 07/10/19

Most Recent Stories

More News
InMed Announces Dosing Initiation in 2nd Phase 1 trial with INM-755

, /PRNewswire/ - ("InMed" or the "Company") (TSX: IN) (OTCQX: IMLFF), a clinical-stage pharmaceutical company developing medications targeting diseases with high unmet medical need and leading the clinical...

IN.TO : 6.88 (+3.77%)
IMLFF : 5.0500 (+3.84%)
InMed Announces Dosing Initiation in 2nd Phase 1 trial with INM-755

TSX:IN OTCQX:IMLFF

IMLFF : 5.0500 (+3.84%)
IN.TO : 6.88 (+3.77%)
InMed Announces Completion of Share Consolidation

InMed Announces Completion of Share Consolidation

IN.TO : 6.88 (+3.77%)
IMLFF : 5.0500 (+3.84%)
InMed Announces Completion of Share Consolidation

Trading of Consolidated Shares on TSX Expected to Begin on July 3 rd , 2020

IMLFF : 5.0500 (+3.84%)
IN.TO : 6.88 (+3.77%)
InMed Introduces IntegraSyn™: An Integrated Cannabinoid Manufacturing System

, /PRNewswire/ - ("InMed" or the "Company") (TSX: IN) (OTCQX: IMLFF), a clinical-stage pharmaceutical company developing medications targeting diseases with high unmet medical need and leading the way...

IN.TO : 6.88 (+3.77%)
IMLFF : 5.0500 (+3.84%)
InMed Introduces IntegraSyn™: An Integrated Cannabinoid Manufacturing System

VANCOUVER, BC , June 24, 2020 /PRNewswire/ - InMed Pharmaceuticals Inc. ("InMed" or the "Company") (TSX: IN) (OTCQX: IMLFF), a clinical-stage pharmaceutical company developing medications targeting...

IMLFF : 5.0500 (+3.84%)
IN.TO : 6.88 (+3.77%)
InMed Announces Filing of Registration Statement in Connection with United States Offering, Application to Seek Nasdaq Listing and Planned Share Consolidation

, /PRNewswire/ -  ("InMed" or the "Company") (TSX: IN) (OTCQX: IMLFF), a clinical-stage pharmaceutical company developing medications targeting diseases with high unmet medical need and leading the...

IN.TO : 6.88 (+3.77%)
IMLFF : 5.0500 (+3.84%)
InMed Announces Filing of Registration Statement in Connection with United States Offering, Application to Seek Nasdaq Listing and Planned Share Consolidation

VANCOUVER, BC , June 19, 2020 /PRNewswire/ -  InMed Pharmaceuticals Inc. ("InMed" or the "Company") (TSX: IN) (OTCQX: IMLFF), a clinical-stage pharmaceutical company developing medications...

IN.TO : 6.88 (+3.77%)
IMLFF : 5.0500 (+3.84%)
InMed Releases CBN Preclinical Results in Glaucoma

, /PRNewswire/ -  ("InMed" or the "Company") (TSX:IN; OTCQX:IMLFF), a clinical-stage pharmaceutical company developing medications targeting diseases with high unmet medical need and leading the way...

IMLFF : 5.0500 (+3.84%)
InMed Releases CBN Preclinical Results in Glaucoma

VANCOUVER , May 27, 2020 /PRNewswire/ -  InMed Pharmaceuticals Inc. ("InMed" or the "Company") (TSX:IN; OTCQX:IMLFF), a clinical-stage pharmaceutical company developing medications targeting...

IMLFF : 5.0500 (+3.84%)
IN.TO : 6.88 (+3.77%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 40% Sell with a Weakest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

The market is approaching oversold territory. Be watchful of a trend reversal.

See More Share

Trade IMLFF with:

Key Turning Points

2nd Resistance Point 5.2877
1st Resistance Point 5.0754
Last Price 5.0500
1st Support Level 4.6754
2nd Support Level 4.4877

See More

52-Week High 11.0880
Fibonacci 61.8% 8.2189
Fibonacci 50% 7.3326
Fibonacci 38.2% 6.4463
Last Price 5.0500
52-Week Low 3.5772

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar